Relmada shares jumped sharply after positive 12-month Phase 2 trial data for NDV-01 in bladder cancer and announcement of $160M financing to advance development.
Leerink starts coverage on Relmada Therapeutics, upgrades the stock to Outperform, and highlights strong potential for its bladder cancer program NDV-01.
Jefferies and BTIG start coverage on Relmada and Invivyd with Buy ratings, citing pipeline shifts, strong assets, and large market potential.
Mizuho upgrades Relmada Therapeutics to Outperform, raising the price target to $10. NDV-01 shows promise in bladder cancer with $2B peak sales potential.
